Merck’s Enflonsia to gain competitive advantage in paediatric RSV prophylaxis market with lack of…
FDA-approved Enflonsia enters US paediatric RSV market as the only prophylactic not requiring weight-based dosing, posing new…
Recover your password.
A password will be e-mailed to you.
Recover your password.
A password will be e-mailed to you.